Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
everolimus + cyclosporin A + prednisolone
- Development stage
- Phase 4
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination immunosuppressive regimen consisting of everolimus (an mTOR inhibitor), cyclosporin A (a calcineurin inhibitor), and prednisolone (a corticosteroid). This triple therapy is used primarily in organ transplantation, especially kidney transplants, to prevent rejection. The combination aims to provide effective immunosuppression while potentially allowing for reduced doses of cyclosporine, which may mitigate calcineurin inhibitor-related nephrotoxicity.
02
Targets
CN (Calcineurin)GR (Glucocorticoid receptor)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on everolimus + cyclosporin A + prednisolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on everolimus + cyclosporin A + prednisolone.